NCT01843205

Buspirone as a Candidate Medication for Methamphetamine Abuse

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: University of Kentucky · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Methamphetamine use disorders are an unrelenting public health concern. Intensive research efforts have yielded behavioral interventions that reduce methamphetamine use, however, these interventions are not universally effective and treatment effects diminish over time. Development of a pharmacotherapy that enhances the efficacy of these interventions is a priority for the National Institute on Drug Abuse. This study proposes to determine the impact of buspirone maintenance on self-administration of methamphetamine. These preliminary data will be used to support further research developing buspirone as a pharmacotherapy for methamphetamine use disorders. The investigators hypothesize that buspirone will attenuate the reinforcing effects of methamphetamine.

Conditions

• Methamphetamine Dependence
• Methamphetamine Abuse

Interventions

Type	Name	Description
DRUG	Methamphetamine	The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.
DRUG	Placebo	The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.

Timeline

• Start date: 2013-04-01
• Primary completion: 2017-03-01
• Completion: 2017-03-01
• First posted: 2013-04-30
• Last updated: 2018-02-07
• Results posted: 2018-02-07

Locations

1 site across 1 country: United States